Advertisement

Hepatology International

, Volume 2, Issue 2, pp 163–178 | Cite as

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

  • Nancy LeungEmail author
Review Article

Abstract

Forty years ago in 1967, Professor Blumberg discovered the Australian Antigen, later known as the hepatitis B surface antigen, and was awarded the Nobel Prize. This discovery enables the diagnosis of hepatitis B virus (HBV) infection and defines its epidemiology. Viral hepatitis B infection affects global health situation, and chronic hepatitis B (CHB) is particularly serious in the Asia-Pacific region. HBV vaccines created the first breakthrough in HBV prevention. Through universal HBV vaccination program for the newborns, promoted since the mid-1980s, the main route that perpetuates chronic infection from mother to child is curbed. Most children and young adults now have immunity against HBV infection. The next breakthrough comes with therapy for CHB. This prevents progression to cirrhosis and hepatocellular carcinoma. Standard interferon therapy with modest efficacy has been largely replaced by therapy with nuclos(t)ide analogues or pegylated interferons alfa-2a and -2b. Lamivudine was approved by the FDA USA in 1998, followed by adefovir dipivoxil in 2002, entecavir in 2005, and telbivudine in 2006. Clevudine, tenofovir, and many promising candidates are in different stages of development and clinical trial. This paper critically reviews recent data published or presented since the APASL Consensus and Guideline Update of 2005. Clinical efficacy mostly in patients with raised serum alanine aminotransferase will be analyzed.

Keywords

Chronic hepatitis B Therapy Nucleos(t)ide analogues 

References

  1. 1.
    Blumberg BS, Gerstley BJ, Hungerford DA, London T, Sutnick AI. A serum antigen (Australia Antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66(5):924–31.PubMedGoogle Scholar
  2. 2.
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepatol. 2004;11:97–107.Google Scholar
  3. 3.
    Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15(12):1356–61. Review.PubMedGoogle Scholar
  4. 4.
    Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139–45.PubMedGoogle Scholar
  5. 5.
    Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.1. Liver Int. 2005;25(3):472–89.Google Scholar
  6. 6.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.PubMedGoogle Scholar
  7. 7.
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.Google Scholar
  8. 8.
    Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5(8):921–31.Google Scholar
  9. 9.
    Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101(8):1797–803.PubMedGoogle Scholar
  10. 10.
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339(2):61–8 (see Editorial).PubMedGoogle Scholar
  11. 11.
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA-positive (precore) chronic hepatitis B. Hepatology. 1999;29:889–96.PubMedGoogle Scholar
  12. 12.
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment of chronic hepatitis B in United States. N Engl J Med. 1999;341:1256–63.PubMedGoogle Scholar
  13. 13.
    Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30(3):770–4.PubMedGoogle Scholar
  14. 14.
    Leung N. Clinical experience with lamivudine. Semin Liver Dis. 2002;22(Suppl 1):15–22.PubMedGoogle Scholar
  15. 15.
    Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology. 2005;48(6):341–9.PubMedGoogle Scholar
  16. 16.
    Guan R, Liaw YF, Leung NWY, et al. Durable HbeAg response in Chinese patients treated with lamivudine. J Gastroenterol Hepatol. 2000;15(Suppl):I106.Google Scholar
  17. 17.
    Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis Be antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345–53.PubMedGoogle Scholar
  18. 18.
    Chien RN, Liaw YF. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Antivir Ther. 2006;11(7):947–52.PubMedGoogle Scholar
  19. 19.
    Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714–22.PubMedGoogle Scholar
  20. 20.
    Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36(6):687–96.PubMedGoogle Scholar
  21. 21.
    Yuen MF, Lai CL. Prediction of treatment outcomes for lamivudine. J Gastroenterol Hepatol. 2007;22(7):964–5.PubMedGoogle Scholar
  22. 22.
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31.Google Scholar
  23. 23.
    Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V. Beneficial effects of ‘lamivudine pulse’ therapy in HBeAg-positive patients with normal ALT. J Viral Hepatol. 2004;11(6):552–8.Google Scholar
  24. 24.
    Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, et al. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther. 2006;23(6):787–95.PubMedGoogle Scholar
  25. 25.
    Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128(7):1890–7.PubMedGoogle Scholar
  26. 26.
    Chan HLY, Wong VW, Tse AML, Tse CH, Chim AML, Chan HY, et al. Serum hepatitis B surface antigen (HBsAg) level can reflect hepatitis B virus in the liver and predict treatment response. J Hepatol. 2007;17(Suppl 46):S186.Google Scholar
  27. 27.
    Thakur V, Sarin SK, Rehman S, Guptan RC, Kazim SN, Kumar S. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol. 2005;24(1):12–5.PubMedGoogle Scholar
  28. 28.
    Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther. 2006;11(6):779–86.PubMedGoogle Scholar
  29. 29.
    Chen JJ, Lin CY, Sheu MJ, Kuo HT, Sun CS, Tang LY, et al. Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation. Aliment Pharmacol Ther. 2006;23(1):85–90.PubMedGoogle Scholar
  30. 30.
    Nakamuta M, Kotoh K, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, et al. Body surface area is an independent factor contributing to the effects of lamivudine treatment. Hepatol Res. 2005;31(1):13–7.Google Scholar
  31. 31.
    Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38(5):1267–73.PubMedGoogle Scholar
  32. 32.
    Shinkai N, Tanaka Y, Orito E, Ito K, Ohno T, Hirashima N, et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res. 2006;36(4):272–6.PubMedGoogle Scholar
  33. 33.
    Jang JW, Bae SH, Choi JY, Kim CW, Han NI, Han JY, et al. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses. J Gastroenterol Hepatol. 2006;21(2):384–91.PubMedGoogle Scholar
  34. 34.
    Shin JW, Park NH, Park JH, Park JH, Jeong ID, Bang SJ, et al. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B. J Viral Hepatol. 2005;12(4):393–7.Google Scholar
  35. 35.
    Hunt CM, McGill JM, Allen MI, et al. Clinical relevance of hepatitis B mutations. Hepatology. 2000;31(5):1037–44.PubMedGoogle Scholar
  36. 36.
    Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol. 2007;22(7):1078–85.PubMedGoogle Scholar
  37. 37.
    Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis e antigen seroconversion rates: results after three years of therapy. Hepatology. 2001;33(6):1527–32.Google Scholar
  38. 38.
    Kazim SN, Chauhan R, Das BC, Sarin SK. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy. J Gastroenterol Hepatol. 2006;21(10):1525–32.PubMedGoogle Scholar
  39. 39.
    Chan HL, Wong VW, Tse CH, Chim AM, Chan HY, Wong GL, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther. 2007;25(8):891–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126(1):91–101.PubMedGoogle Scholar
  41. 41.
    Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126(1):81–90.PubMedGoogle Scholar
  42. 42.
    Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2007;46(Suppl 1):S191.Google Scholar
  43. 43.
    Lee HI, Lee JH, Tak WY, Hwang JS, Bae SH, Lee TH, et al. Overlapping of lamivudine and adefovir before switching to adefovir monotherapy in lamivudine resistant chronic hepatitis B: is it necessary? J Hepatol. 2007;46(Suppl 1):S191.Google Scholar
  44. 44.
    van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, et al. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol. 2007;22(9):1500–6.Google Scholar
  45. 45.
    Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepatol. 2006;13(4):250–5.Google Scholar
  46. 46.
    Hézode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol. 2007;46(5):791–6.PubMedGoogle Scholar
  47. 47.
    Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–49.Google Scholar
  48. 48.
    Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51(3):902–11.PubMedGoogle Scholar
  49. 49.
    Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46(3):531–8.PubMedGoogle Scholar
  50. 50.
    Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepatol. 2005;12(4):386–92.Google Scholar
  51. 51.
    Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis. 2003;23(1):89–100 (review).PubMedGoogle Scholar
  52. 52.
    Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007;46(4):1049–56.Google Scholar
  53. 53.
    Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106(6):1320–5.PubMedGoogle Scholar
  54. 54.
    Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology. 2006;43(2):225–32.PubMedGoogle Scholar
  55. 55.
    Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther. 2004;9(5):729–32.PubMedGoogle Scholar
  56. 56.
    Yilmaz A, Akcam M, Gelen T, Artan R. Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center’s experience. Eur J Pediatr. 2007;166(3):195–9.PubMedGoogle Scholar
  57. 57.
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528–36.Google Scholar
  58. 58.
    Chan HL, Wong VW, Chim AM, Choi PC, Chan HY, Hui AY, et al. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther. 2007;12(5):815–23.PubMedGoogle Scholar
  59. 59.
    Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol. 2007;102(1):96–104.Google Scholar
  60. 60.
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808–16.Google Scholar
  61. 61.
    Chang T, Shiffman ML, Tong M, et al. Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. Gastroenterology. 2006;130:A-846 [#T1844].Google Scholar
  62. 62.
    Zeng M, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44(1):108–16.PubMedGoogle Scholar
  63. 63.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):800–7. Erratum in: N Engl J Med. 2003;348(12):1192.Google Scholar
  64. 64.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–51.Google Scholar
  65. 65.
    Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos NC. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology. 2006;44(Suppl 4):231A.Google Scholar
  66. 66.
    Laras A, Kostamena A, Hadziyannis SJ. HBV cccDNA pregenomic RNA and total HBV DNA levels in the liver of HBeAg-negative CHB patients under long term antiviral therapy. J Hepatol. 2007;46(Suppl 1):S28.Google Scholar
  67. 67.
    Westland C, Delaney W IV, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003;125(1):107–16.PubMedGoogle Scholar
  68. 68.
    Lim S, Marcellin P, Tassopoulos N, Hadziyannis S, Chang T, Tong M, et al. Effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther. 2007;26(10):1419–28.Google Scholar
  69. 69.
    Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354:1807–12.PubMedGoogle Scholar
  70. 70.
    Kim DY, Lee JH, Lee DH, et al. Occurrence of primary adefovir resistance mutation in hepatitis B patients with YMDD mutation and lamivudine resistance. Gastroenterology. 2006;130:A–846 [#T1843].Google Scholar
  71. 71.
    Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol. 2007;47(3):366–72.PubMedGoogle Scholar
  72. 72.
    Yeon JE. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55(10):1488–95.PubMedGoogle Scholar
  73. 73.
    Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther. 2006;11(6):771–8.PubMedGoogle Scholar
  74. 74.
    Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther. 2007;12(1):41–6.PubMedGoogle Scholar
  75. 75.
    Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44(2):283–90.PubMedGoogle Scholar
  76. 76.
    Kaymakoglu S, Idilman R, Ahishali E, Onder FO, Bektas M, Badur S, et al. High baseline HBV-DNA is linked to the emergence of adefovir resistance in lamivudine resistant patients. J Hepatol. 2007;46(Suppl 1):S189.Google Scholar
  77. 77.
    Liaw YF. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology. 2007;45(2):266–8. [Comment in: Hepatology. 2007;45(2):307–13.]PubMedGoogle Scholar
  78. 78.
    Schiff E, Lai CL, Neuhaus P, et al. Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation. Gastroenterology. 2006;130:A-765 [abstract #480].Google Scholar
  79. 79.
    Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13(3):349–60.PubMedGoogle Scholar
  80. 80.
    van Bommel F. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44(2):318–25. [Comment in: Hepatology. 2006;44(2):309–13.]PubMedGoogle Scholar
  81. 81.
    Chang TT, Lai CL. Hepatitis B virus with primary resistance to adefovir. New Engl J Med. 2006;355(34):322–3 (author reply 323). [Comment in: N Engl J Med. 2006;354(17):1807–12.]PubMedGoogle Scholar
  82. 82.
    Santos SA, Uriel AJ, Park JS, Lucas J, Carriero D, Jaffe D, et al. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol. 2006;18(12):1247–53.PubMedGoogle Scholar
  83. 83.
    Sokal E, Kelly D, Wirth S, Mizerski J, Lu B, Kleber K, et al. The paharmacokinetics (PK) and safety of a single dose of adefovir dipivoxil (ADV) in children and adolescents aged 2–17) with chronic hepatitis B. J Heptol. 2004;40(Suppl 1):132.Google Scholar
  84. 84.
    Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med. 2005;352(3):310–1.PubMedGoogle Scholar
  85. 85.
    Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–84.PubMedGoogle Scholar
  86. 86.
    Colonna RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in woodchuck model of chronic hepatitis infection. J Infect Dis. 2001;184:1236–45.Google Scholar
  87. 87.
    Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother. 2002;46(1):82–8.PubMedGoogle Scholar
  88. 88.
    Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81(8):3992–4001.Google Scholar
  89. 89.
    Billich A. Entecavir (Bristol-Myers Squibb). Curr Opin Investig Drugs. 2001;2(5):617–21 (review).PubMedGoogle Scholar
  90. 90.
    Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol. 2002;37(1):137–44. Erratum in: J Hepatol. 2002;37(5):708.PubMedGoogle Scholar
  91. 91.
    de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with CHB. Hepatology. 2001;34(3):578–82.PubMedGoogle Scholar
  92. 92.
    Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123(6):1831–8.PubMedGoogle Scholar
  93. 93.
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–10.Google Scholar
  94. 94.
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–20. Erratum in: N Engl J Med. 2006;354(17):1863.Google Scholar
  95. 95.
    Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129(4):1198–209.Google Scholar
  96. 96.
    Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006;11(7):909–16.PubMedGoogle Scholar
  97. 97.
    Leung N, Peng C-Y, Sollano J, Lesmana L, Yuen M-F, Jeffers L, Hann H-W, et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive Adults: 24 WK Results (E.A.R.L.Y. Study). Hepatology. 2006;44(Suppl 4):554A.Google Scholar
  98. 98.
    Chang TT, Chao YC, Kaymakoglu S, Cheinquer H, Pessoa M, Gish RG, et al. Entecavir maintained virological suppression through three years of treatment in antiviral-naïve HBEAG(+) patients (ETV 022/901). Hepatology. 2006;44(Suppl 4):229A.Google Scholar
  99. 99.
    Han S, Chan TT, Chao YC, Yoon SK, Gish RG, Cheinquer H, et al. Four-year entecavir treatment in nucleoside-naïve HBeAg (+) patients: results from studies ETV-022 and -901 Hepatology. 2007;46(4 Suppl 1):654A.Google Scholar
  100. 100.
    Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, et al. A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B. Zhonghua Nei Ke Za Zhi. 2006;45(11):891–5 (Chinese).PubMedGoogle Scholar
  101. 101.
    Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother. 2007;60(2):201–5.PubMedGoogle Scholar
  102. 102.
    Yao G, Chen CW, Lu WL, Ren H, Tan DM, Wang YM, et al. Entecavir achieves superior virologic response compared to lamivudine for the treatment of chronic hepatitis B: 2 year results from a phase 3 study in nucleoside-naïve patients in China. Hepatology. 2006;44(Suppl 1):559A.Google Scholar
  103. 103.
    Senturk H, Lurie Y, Gadano A, et al. ETV re-treatment of nucleoside-naïve HBeAg(-) patients. J Hepatol. 2007;46(Suppl 1):S197.Google Scholar
  104. 104.
    Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44(6):1656–65. [Comment in: Gut. 2005;54(11):1521–3. Gut. 2006;55(5):745; author reply 745–6.]Google Scholar
  105. 105.
    Colonno R, Rose R, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients Hepatology. 2006;44(Suppl 4):229A.Google Scholar
  106. 106.
    Colonno R, Rose R, Pokornowski K, Baldick CJ, Eggers B, Yu D, et al. Four years assessment of entecavir resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol. 2007;46(Suppl 1):S294.Google Scholar
  107. 107.
    Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–49.Google Scholar
  108. 108.
    Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51(3):902–11.PubMedGoogle Scholar
  109. 109.
    Simsek H, Schiff E, Goodman Z, Brett-Smith H, Klesczewski K, Kreter B. Efficacy of entecavir and lamivudine in chronic hepatitis B patients with advanced fibrosis/cirrhosis J Hepatol. 2007;46(Suppl 1):S197.Google Scholar
  110. 110.
    Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol. 2006;36(1):8–12. Epub 2006 Mar 3. Review.PubMedGoogle Scholar
  111. 111.
    Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162–70. Review.Google Scholar
  112. 112.
    McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med. 2007;356(25):2614–21.PubMedGoogle Scholar
  113. 113.
    Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, Yuen MF, Chao GC, Myers MW. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004;40(3):719–26.PubMedGoogle Scholar
  114. 114.
    Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother. 2006;50(3):874–9.PubMedGoogle Scholar
  115. 115.
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528–36.Google Scholar
  116. 116.
    Rasenack J, Poynard T, Lai CL, Gane E, Brown N, Heathcoate EJ. Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines. J Hepatol. 2007;46(Suppl 1):S195.Google Scholar
  117. 117.
    Gane E, Lai CL, Min A, Heathcoate J, Poynard T, Kurdas OO, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study. J Hepatol. 2007;46(Suppl 1):S187.Google Scholar
  118. 118.
    Poynard T, Chutaputt A, Hwang SG, Lim SG, Heathcoate J, Kuan YY, et al. Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study. J Hepatol. 2007;46(Suppl 1):S27.Google Scholar
  119. 119.
    Marcellin P, Chan HLY, Lai CL, Cho M, Moon YM, Chao YC, et al. 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switch from adefovir to telbivudine. J Hepatol. 2007;46(Suppl 1):S55.Google Scholar
  120. 120.
    Marcellin P, Chan HLY, Lai CL, Cho M, Heathcote J, Moon YM, et al. In hepatitis B patients treated with either adefovir or telbivudine, maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy. J Hepatol. 2007;46(Suppl 1):S193.Google Scholar
  121. 121.
    Safadi R, Xie Q, Chen Y, Yin YK, Wei L, Hwang SG, et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24. J Hepatol. 2007;46(Suppl 1):S196.Google Scholar
  122. 122.
    Keam SJ. Telbivudine. Drugs. 2007;67(13):1917–29 (Review).Google Scholar
  123. 123.
    Brown CA, Smith F, Laessig KA. Creatine kinase (CK) elevations and muscle toxicity associated with chronic telbivudine (LdT) use in prospective clinical trials. Hepatology. 2007;46(4 Suppl 1):655A.Google Scholar
  124. 124.
    Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166(1):49–56. [Comment in: Arch Intern Med. 2006;166(1):9–12.]Google Scholar
  125. 125.
    Korba BE, Cote PJ, Menne S, Toshkov I, Baldwin BH, Wells FV, et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection Antivir Ther. 2004;9(6):937–52.PubMedGoogle Scholar
  126. 126.
    Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther. 2006;4(4):549–61 (review).PubMedGoogle Scholar
  127. 127.
    Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006;43(5):982–8.PubMedGoogle Scholar
  128. 128.
    Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis Be antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46(4):1041–8.PubMedGoogle Scholar
  129. 129.
    Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007;45(5):1172–8.PubMedGoogle Scholar
  130. 130.
    Lee KS, Byun KS, Chung YH, Paik SW, Han JY, Yoo K, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology. 2007;50(4):296–302.PubMedGoogle Scholar
  131. 131.
    Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother. 2006;50(5):1642–8.PubMedGoogle Scholar
  132. 132.
    van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44(2):318–25. [Comment in: Hepatology. 2006;44(2):309–13.]PubMedGoogle Scholar
  133. 133.
    van Bömmel F, De Man RA, Erhardt A, Huppe D, Stein K, Buggisch P, et al. First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection. Hepatology. 2007;46(4 Suppl 1):270A.Google Scholar
  134. 134.
    Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174–0102. Hepatology. 2007;46(4 Suppl 1):80A.Google Scholar
  135. 135.
    Heathcoate EJ, Gane E, De Man R, Lee S, Flisiak R, Mann MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB): study GS-US-174–0103. Hepatology. 2007;46(4 Suppl 1):861A.Google Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2008

Authors and Affiliations

  1. 1.Department of MedicineAlice Ho Miu Ling Nethersole HospitalTaipoHong Kong
  2. 2.The Chinese University of Hong KongShatinHong Kong SAR, China

Personalised recommendations